CD8A and neoplasm: Further assessment of baseline spatial co-clustering of immune cells revealed that relatlimab alone was characterized by significant clustering of CD8+ with Tregs within tumor regions (p=0.026 and p=0.01 compared nivolumab and combination lead-in arms, respectively) with CD8+ and FOXP3+ Treg clustering associated with worse PFS (p=0.018) (Fig. 3 E, F).